Global Pulmonary Arterial Hypertension (PAH) Market: Snapshot

Pulmonary arterial hypertension (PAH) is a very rare type of progressive disorder related to high blood pressure. However, the rate of incidence of this disorder is gradually gaining traction. Various sources, including WHO and CDC, suggest that the global prevalence of PAH is anticipated to be between 100,000 and 200,000, narrowing down to about 15-50 cases per million heads. There is no permanent cure for PAH available in the market, which renders the market highly opportunistic. According to a report by Transparency Market Research (TMR), the global PAH market is estimated to reach a valuation of US$5.19 bn by the end of 2020, expanding at a tremendous CAGR of 17.90% between 2014 and 2020.

Several treatments are available to control symptoms, slow down the progression of the disease, and enhance the quality of life. The approval of some effective drugs in recent times and the presence of a promising pipeline are among the primary factors providing a significant boost to the global pulmonary arterial hypertension market. Favorable government initiatives are also playing a vital role in the development of the market.

A TMR analyst states that however, the patent expiry of some of the blockbuster drugs are paving way for penetration of generic drugs. Generic drugs are usually 70% to 80% cheaper than branded drugs and therefore, their increased sales adversely affect the overall revenue generation of the market. On the other hand, the future of the global market looks bright with the development of cutting-edge therapies for the treatment of PAH.

Prostacyclin and Prostacyclin Analogs to Rise to Forefront during Forecast Period

On the basis of drug class, the report segments the global PAH market into PDE-5 inhibitors, endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (sGC) stimulators and selexipag. The ERAs segment dominated the market in terms of value at the beginning of the forecast period. However, by the end of this period, the prostacyclin and prostacyclin analogs segment will surpass ERAs. The growth of the segment can be mainly attributed to the approval of new drugs such as Uptravi (selexipag) in December 2015 and Orenitram (treprostinil) in December 2013. While in the case of sGC stimulator, Adempas (riociguat) is the only approved drug for the treatment of PAH.

Availability of Newly-approved PAH Drugs to Fuel Dominance of North America

North America will continue to account for the lion’s share until 2020, closely trailed by Europe. These two developed regions will exhibit remarkable growth during the forecast period, thanks to the availability of newly-approved PAH drugs along with the presence of a promising pipeline. The high awareness among the populace regarding the availability of treatment for pulmonary arterial hypertension is also driving the growth of the regions.

The Asia Pacific market will also be highly opportunistic in nature. Countries such as Japan, Australia, India, New Zealand, and China will be sights of high growth rates in the region and therefore, will be emerging destinations for global players. Rest of the World, on the other hand, is likely to register sluggish growth during the same period. The lack of awareness related to the detection and treatment of PAH is acting as a bottleneck in the development of the region.

Some of the prominent participants in the global pulmonary arterial hypertension market are Gilead Sciences Inc., Actelion Pharmaceuticals Ltd., GlaxoSmithKline Plc., Bayer HealthCare, Novartis International AG, Pfizer Inc., and United Therapeutics Corp. 

Pulmonary arterial hypertension (PAH) is a progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH is a very rare condition that occurs when pulmonary arteries become narrow in diameter or get blocked. This report on the global pulmonary arterial hypertension (PAH) market offers an insightful and in-depth assessment of the current and future market potential of PAH drugs. The research study has been divided into eight chapters namely, preface, executive summary, global PAH market overview, global PAH market revenue by drug class, PAH market pipeline analysis, global PAH market revenue by geography, recommendations, and company profiles.
The executive summary chapter covers a market snapshot representing key findings from the study on the global PAH market. The market overview chapter of the report comprises qualitative analysis of the overall PAH market, considering factors determining market dynamics such as growth drivers, restraints, and opportunities. This chapter also includes a section on epidemiology of PAH. A section on the event impact analysis has also been provided in the market overview chapter of the report on the PAH market. In the competitive landscape section, the market revenue share of key players operating in the PAH market in terms of percentage in 2013 has been provided. The market share analysis of key players involved a study of the company’s product/service portfolio and sales revenue along with the geographical presence.
In chapter four, the global PAH market has been segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators, based on the commercially-available drug classes, to treat PAH. The market revenue size for each segment has been provided in terms of USD million in the chapter for the period from 2012 to 2020, along with the CAGR for the forecast period between 2014 and 2020, considering 2012 and 2013 as the base years. The chapter also provides qualitative analysis for each segment, based on factors such as market trends, recent developments, future outlook, and opportunities.
Chapter five deals with the pipeline analysis of the PAH market and comprises information such as major steps involved in the development and commercialization of a drug, tabular presentation of early-stage drug candidates, and extensive analysis and future sales projection of the late-stage drug candidate, Uptravi (selexipag).
Geographically, the global PAH market has been classified into four major regions namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market size and forecast for each of these regions along with the CAGR has been provided in the report.
The study on the global PAH market also suggests a list of recommendations for new companies aspiring to enter the market and existing companies willing to accentuate revenue shares. The report concludes with the profiles of major players in the global PAH market such as Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation. Each company profile in the report provides information under the heads: company overview, financial overview, product portfolio, business strategies, and recent developments.
The company overview section comprises basic information about the company such as major business areas, company’s brief history and its establishment year, number of employees, and geographical presence. In the financial overview section, annual revenue for the last three consecutive years (2011, 2012, and 2013) has been provided. The business strategies section mentions key strategies adopted by a company in the past to strengthen its position in the PAH market. The recent developments section shares information about the recent activities of the companies operating in the PAH market.
The global PAH market is segmented as follows:
Global Pulmonary Arterial Hypertension Market, by Drug Class
  • Prostacyclin and Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
Pipeline Analysis: Pulmonary Arterial Hypertension Market
  • Early-stage Drug Candidates (Phase I & Phase II)
  • Late-stage Drug Candidates (Phase III & Registration Phase)
Global Pulmonary Arterial Hypertension Market, by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)